BioXcel Therapeutics
BTAI
BTAI
85 hedge funds and large institutions have $140M invested in BioXcel Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
85
Holders Change
-9
Holders Change %
-9.57%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
32
Reduced
28
Closed
15
Calls
$2.56M
Puts
$933K
Net Calls
+$1.62M
Net Calls Change
+$1.19M
Top Buyers
1 |
Nuveen Asset Management
Chicago,
Illinois
|
$2.57M |
2 |
BlackRock
New York
|
$17.3M |
3 |
Vanguard Group
Malvern,
Pennsylvania
|
$12.2M |
4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
$5.37M |
5 |
Morgan Stanley
New York
|
$3.01M |